| ABSTRACT Objective:To observe the influence of bifid triple viable capsules adjuvant therapy to the intestinal flora, plasma endotoxin and intestinal mucosal barrier function of the patients with cirrhosis.Methods:70 patients with cirrhosis were randomly divided to control group (35 cases) and observation group (35 cases). The patients of control group were given symptomatic supportive treatment, and the observation group was treated with bifid triple viable capsules on the basis of control group, a course of 4 weeks. The changes of intestinal microflora (escherichia coli, enterococci, bifidobacteria, lactobacillus, yeast like fungi), the plasma levels of endotoxin, and the intestinal mucosa barrier function such as PCT and diamine oxidase (DAO) in the two groups before and after treatment were compared. Results:After the treatment, the colonies number of escherichia coli, enterococci, bifidobacteria, lactobacillus in the observation group after treatment was significantly higher than that of before treatment and the control group after treatment(P<0.05), and the colonies number of yeast like fungi were significantly lower than that of before treatment and the control group after treatment(P<0.05). The expression level of plasma endotoxin, PCT, DAO in the two groups after treatment significantly decreased than that of before treatment (P<0.05), and the observation group decreased significantly compared with the control group (P<0.05). There was no serious adverse drug reaction occurred during the treatment in the two groups. Conclusion:The bifid triple viable capsules adjuvant therapy could promote the recovery of intestinal flora in patients with cirrhosis, reduce the level of plasma endotoxin, improve the intestinal mucosal barrier function, and it was worthy of clinical application. |
